ImageneBio (IMA) Interest Coverage Ratio (2022 - 2023)
ImageneBio's (IMA) quarterly Interest Coverage Ratio came in at 1564.86 in Q4 2023, down 131.06% year-on-year from 5038.0 in Q4 2022, and up 83.95% quarter-over-quarter from 9751.5 in Q3 2023.
ImageneBio (IMA) Interest Coverage Ratio (2022 - 2023) Analysis & Trends
ImageneBio has disclosed Interest Coverage Ratio across 2 years of filings, most recently posting 1564.86 for Q4 2023.
- Interest Coverage Ratio for Q4 2023 came in at 1564.86, down 131.06% year-over-year; the trailing twelve-month figure through Sep 2024 was 4142.36 (up 69.82% YoY), and the FY2023 annual result was 3428.05, up 51.65% from the prior year.
- Interest Coverage Ratio came in at 1564.86 for Q4 2023 at ImageneBio, up from 9751.5 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 5038.0 in Q4 2022 to a low of 9751.5 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | ImageneBio | 3.18 Mn | 3.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,564.86 |
| Sep 30, 2023 | -9,751.50 |
| Jun 30, 2023 | -3,081.67 |
| Dec 31, 2022 | 5,038.00 |
| Sep 30, 2022 | -1,489.67 |
| Jun 30, 2022 | -445.77 |
| Mar 31, 2022 | -346.16 |